News & Updates
Search Research Content
Resource Finder at Kennedy Krieger Institute
A free resource that provides access to information and support for individuals and families living with developmental disabilities.
Polymorphisms in ERCC1 C8092A predict progression-free survival in metastatic/recurrent nasopharyngeal carcinoma treated with cisplatin-based chemotherapy.
|Title||Polymorphisms in ERCC1 C8092A predict progression-free survival in metastatic/recurrent nasopharyngeal carcinoma treated with cisplatin-based chemotherapy.|
|Publication Type||Journal Article|
|Year of Publication||2013|
|Authors||Chen C, Wang F, Wang Z, Li C, Luo H, Liang Y, An X, Shao J, Li Y|
|Journal||Cancer chemotherapy and pharmacology|
|Date Published||2013 Aug|
We evaluated whether DNA repair gene polymorphisms had an effect on clinical outcomes in metastatic/recurrent nasopharyngeal carcinoma (NPC) patients treated with cisplatin-based chemotherapy.
|Alternate Journal||Cancer Chemother. Pharmacol.|